Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
The aim is not only to urge people to get regular eye exams, but also to maintain good health, as many other preventable diseases like diabetes can lead to vision loss.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
The bill, if enacted, would publicly share information about industry payments to physician assistants and nurse practitioners.
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
A bout with Lyme disease led Yee to found a company that helps patients measure and track their breathing patterns.
A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.
Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial
Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.
The annual awards program has added three new categories.
The drugmaker previously launched an unbranded campaign about lung-cancer biomarkers.
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
One pharmacy director would like to see a lot more comparative data about new therapies.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
Transportation barriers can limit patient involvement in clinical trials.
Docs said patients asked about drugs from DTC ads six times in a typical week, compared to just twice a week five years ago.
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
But it may also increase the reporting burden for drugmakers.
BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
How the retail pharmacy chain uses customer data to make its marketing messages relevant.
Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
The regulator is providing examples of appropriate off-label communications.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Deborah Furey will lead the agency's pilot of a new personalized marketing offering.
MM&M last year named its inaugural class of 16 Femmes and 20 Women to Watch. Who should be considered for this year's list of breakthough women?
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
The agency issued 11 enforcement letters last year.
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.
"In Australia, we are the healthcare industry," he says.
CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal
The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.
There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
J&J's CEO may be right. Customers of all kinds are demanding change.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
DeViteri started in the newly created role this month.
The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
The new agency will focus on marketing goods and services to people 50 years of age and older.
She says her experience in consumer brands helps her push healthcare clients to be more creative.
Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending
The agency has faced questions about how it regulates off-label communications.
Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales
The merger of Quintiles and IMS Health closed in October.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
With 2016 in the rearview, here are four stats detailing how the FDA fared last year in enforcing regulations and approving new drugs.
Facebook and Instagram are the primary location for brands to engage with online tribes, while Raptr and PlayFire are a hit with boomers.
The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000
The first step is to seek leadership support, she says.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products
We at MM&M found out just how much pharma marketers love a list. Here, read through the year's most-read technology stories.
Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013
Find out what stories generated the most interest among our readers.
Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug
When the vision company needed to demonstrate to parents the plight of children struggling to see, it turned to Olson 1to1 and a 360 video to tell the story.
Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"
Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.
GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores
The agency has sent nine untitled and warning letters so far this year.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm
For years pharma has said it needs to be more focused on patients, has it delivered?